{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:38:24Z","timestamp":1792028304121,"version":"4.4.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"Background<\/jats:title>Carbapenem-resistant gram-negative bacterial (CRGNB) infections are increasing among kidney transplant recipients, and effective therapeutic options are limited. This study aimed to investigate the efficacy and adverse events associated with combination therapy tigecycline in renal transplant patients with CRGNB infections.<\/jats:p><\/jats:sec>Methods<\/jats:title>This study retrospectively analyzed 40 Chinese patients with confirmed or suspected CRGNB infections who received tigecycline therapy. The patients\u2019 case features and clinical and microbiological data were analyzed.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 40 renal transplant recipients received tigecycline therapy for a median duration of 9 (range, 3\u201325) days. CRGNB isolates were obtained from the organ preservation solution of the donor kidney in 28 patients, with confirmed transmission in 4 patients. Infections were detected in the bloodstream, urinary tract, sputum, and wound. The most prevalent isolates were Klebsiella pneumoniae<\/jats:italic> (75%, 30\/40), Acinetobacter baumannii<\/jats:italic> (15%, 6\/40), and Escherichia coli<\/jats:italic> (10%, 4\/40). A clinical response was observed in 32 (80%) patients. The 28-day all-cause mortality rate was 7.5% (3\/40), while the one-year all-cause mortality rate was 2.5% (1\/40). While one patient died owing to severe pancreatitis, no serious adverse events related to tigecycline therapy were reported. However, multiple indices of liver function and pancreatitis precursors increased after treatment with tigecycline compared to before treatment.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Tigecycline therapy appears to be well tolerated in renal transplant recipients with multidrug-resistant bacterial infections. Nevertheless, attention should be paid to adverse reactions related to tigecycline therapy, especially gastrointestinal reactions, and the related laboratory tests should be closely monitored.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1215288","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:01:16Z","timestamp":1699970476000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and effectiveness of tigecycline combination therapy in renal transplant patients with infection due to carbapenem-resistant gram-negative bacteria"],"prefix":"10.3389","volume":"13","author":[{"given":"Qin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoliang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1097\/MJT.0000000000000763","article-title":"Tigecycline-associated acute pancreatitis","volume":"25","author":"Akhter","year":"2018","journal-title":"Am. J. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00134-014-3343-3","article-title":"Is there a future for tigecycline","volume":"40","author":"Bassetti","year":"2014","journal-title":"Intensive Care Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1399-3062.2011.00688.x","article-title":"Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation","volume":"14","author":"Bergamasco","year":"2012","journal-title":"Transpl. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/TP.0b013e3182a049fd","article-title":"Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients","volume":"96","author":"Bodro","year":"2013","journal-title":"Transplantation"},{"key":"B5","first-page":"1672","article-title":"One case of severe hepatic injury caused by tigecycline","volume":"15","author":"Cheng Gy","year":"2018","journal-title":"Chin. J. Drug Appl. Monitor."},{"key":"B6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/nep.13594","article-title":"Beware of drug interaction between tigecycline and tacrolimus","volume":"25","author":"Chow","year":"2020","journal-title":"Nephrol. (Carlton)."},{"key":"B7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-2334-14-102","article-title":"Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13613-020-00715-2","article-title":"Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections","volume":"10","author":"De Pascale","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit. Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam","author":"Ellis-Grosse","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1128\/AAC.01222-13","article-title":"Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence","volume":"58","author":"Falagas","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2014.01.006","article-title":"Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections","volume":"44","author":"Falagas","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/FTD.0000000000000784","article-title":"Safety and efficacy of tigecycline in intensive care unit patients based on therapeutic drug monitoring","volume":"42","author":"Fan","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/jcpt.13212","article-title":"Analysis of clinical characteristics of tigecycline-induced acute pancreatitis","volume":"45","author":"Fang","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/00365540801938949","article-title":"Acute pancreatitis related to tigecycline: case report and review of the literature","volume":"40","author":"Gilson","year":"2008","journal-title":"Scand. J. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017091","article-title":"Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: A meta-analysis","volume":"98","author":"Gong","year":"2019","journal-title":"Med. (Baltimore)."},{"key":"B17","first-page":"964","article-title":"Expert consensus on polymyxins, tigecycline and ceftazidine\/avibactam suseptibility testing","volume":"43","author":"Hui","year":"2020","journal-title":"Chin. J. Lab. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4067\/S0716-10182012000300011","article-title":"[Experience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae]","volume":"29","author":"Hurtado","year":"2012","journal-title":"Rev. Chil. Infectol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1248\/bpb.35.967","article-title":"Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system","volume":"35","author":"Kadoyama","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"B20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.diagmicrobio.2013.08.011","article-title":"Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: a multicenter study in Korea","volume":"78","author":"Kim","year":"2014","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123706","article-title":"Incidence of carbapenem-resistant gram negatives in Italian transplant recipients: a nationwide surveillance study","volume":"10","author":"Lanini","year":"2015","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1080\/1120009X.2020.1800318","article-title":"Optimization of tigecycline dosage regimen for different infections in the patients with hepatic or renal impairment","volume":"32","author":"Li","year":"2020","journal-title":"J. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jmii.2013.04.008","article-title":"Tigecycline salvage therapy for necrotizing fasciitis caused by Vibrio vulnificus: Case report in a child","volume":"49","author":"Lin","year":"2016","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12879-018-3103-z","article-title":"Tigecycline-induced acute pancreatitis in a renal transplant patient: a case report and literature review","volume":"18","author":"Lin","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/jcpt.13269","article-title":"Acute pancreatitis due to tacrolimus in kidney transplant and review of the literature","volume":"46","author":"Liu","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1111\/ajt.13317","article-title":"Outcome of transplantation using organs from donors infected or colonized with carbapenem-resistant gram-negative bacteria","volume":"15","author":"Mularoni","year":"2015","journal-title":"Am. J. Transplant."},{"key":"B27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jiac.2022.03.003","article-title":"Drug use investigation on the safety and efficacy of tigecycline in Japan (all-case post-marketing surveillance)","volume":"28","author":"Ohashi","year":"2022","journal-title":"J. Infect. Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/phar.1159","article-title":"Tigecycline-related pancreatitis: a review of spontaneous adverse event reports","volume":"33","author":"Okon","year":"2013","journal-title":"Pharmacotherapy"},{"key":"B29","first-page":"59","article-title":"Successful treatment of multidrug-resistant Escherichia coli bacteremia with tigecycline in an acute myeloid leukemia child","volume":"54","author":"Ozdemir","year":"2012","journal-title":"Turk. J. Pediatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/j.ajkd.2010.10.040","article-title":"Altered bioavailability of tacrolimus following intravenous administration of tigecycline","volume":"57","author":"Pavan","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/tid.12450","article-title":"Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients","volume":"17","author":"Pouch","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/tid.12276","article-title":"Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients: a case-control study","volume":"16","author":"Simkins","year":"2014","journal-title":"Transpl. Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2008.04.009","article-title":"Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia","volume":"61","author":"Tanaseanu","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s11596-021-2397-z","article-title":"Treatment of Donor-derived Carbapenem-resistant Klebsiella pneumoniae Infection after Renal Transplantation with Tigecycline and Extended-infusion Meropenem","volume":"41","author":"Wang","year":"2021","journal-title":"Curr. Med. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13756-018-0355-8","article-title":"Epidemiology of carbapenem-resistant Klebsiella pneumoniae bloodstream infections after renal transplantation from donation after cardiac death in a Chinese hospital: a case series analysis","volume":"7","author":"Wang","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13593","article-title":"A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors","volume":"23","author":"Yazirli","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: A systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv. Ther."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1215288\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:01:32Z","timestamp":1699970492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1215288\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":37,"alternative-id":["10.3389\/fcimb.2023.1215288"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1215288","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"article-number":"1215288"}}